PADMANEE SHARMA to Risk Assessment
This is a "connection" page, showing publications PADMANEE SHARMA has written about Risk Assessment.
Connection Strength
0.031
-
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
Score: 0.016
-
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. J Clin Oncol. 2017 Dec 01; 35(34):3851-3858.
Score: 0.015